Document is current
Any future updates will be listed below
-
Authors
Mor, Eyal https://orcid.org/0000-0002-3235-2946
Apte, Sameer
Mitchell, Catherine
Nessim, Carolyn
Almond, Max
Vincenzi, Bruno
Lopez, Jose Antonio Gonzalez
Cranmer, Lee
Wagner, Michael J.
Nissan, Aviram
Abreu, Miguel Henriques
Albertsmeier, Markus
Knoblauch, Mathilda
Barlow, Adam
Keung, Emily Z.
Grignani, Giovanni
Hornick, Jason L.
Gronchi, Alessandro
Gyorki, David E.
- License Information
-
More Information
Article History
First Online: 1 September 2025
Disclosures
: Michael J. Wagner reports consulting/advisory board fees from Adaptimmune, Deciphera, Aadi, Epizyme, PharmaEssentia, and Springworks, and research support from Edgewood Oncology. Giovanni Grignani reports honoraria from Bayer, Eisai, Eli Lilly and Company, Merck, Novartis, Pfizer, PharmaMar, Incyte, Decyphera, and Boehringer Ingelheim; consulting or advisory role for Bayer, Eisai, Eli Lilly and Company, Novartis, Pfizer, and PharmaMar; and research funding from Bayer, Novartis, and PharmaMar. Jason L. Hornick reports a consultancy role for Aadi Bioscience, TRACON Pharmaceuticals, and Adaptimmune. Eyal Mor, Sameer Apte, Catherine Mitchell, Carolyn Nessim, Max Almond, Bruno Vincenzi, Jose Antonio Gonzalez Lopez, Lee Cranmer, Aviram Nissan, Miguel Henriques Abreu, Markus Albertsmeier, Mathilda Knoblauch, Adam Barlow, Emily Z. Keung, Alessandro Gronchi, and David E. Gyorki have no disclosures to declare that may be relevant to the contents of this study.
